Stock ALNY ALNYLAM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
150 USD +4.18% Intraday chart for Alnylam Pharmaceuticals, Inc. +4.28% -21.66%
Apr. 30 Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia CI
Apr. 08 Sector Update: Health Care Stocks Flat to Higher Premarket Monday MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
Sector Update: Health Care
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Chevron, Take-Two, Coinbase, Netflix, American Tower...
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
ETF der Woche: Auf die Wende der Biotechs setzen
L'ETF della settimana: scommettere sull'inversione di tendenza delle biotech
ETF van de week: inzetten op de ommekeer in de biotech
ETF de la semaine : miser sur le retournement des Biotechs
Alnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegen
Alnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standards
Alnylam Pharmaceuticals Says Phase 2 Study of Hypertension Drug Zilebesiran Meets Primary Endpoint
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,540,071, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $455,357, According to a Recent SEC Filing
RECOMENDACIONES DE LOS ANALISTAS EE.UU. : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever....
Alnylam Pharmaceuticals' Shares Fall on Q4 Revenue Miss
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Alnylam Pharmaceuticals Q4 Non-GAAP Loss Narrows, Revenue Rises
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALNY Stock
  4. News Alnylam Pharmaceuticals, Inc.
  5. Other languages